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1. Introduction 
Lactic acid bacteria (LAB) constitute a group of Gram-positive nonsporing nonrespiring 
bacteria, cocci or rods, that produce lactic acid as the major end product during the 
fermentation of carbohydrates. The term LAB is associated with bacteria involved in food 
fermentation and bacteria normally associated with the mucosal surfaces of human and 
animals. The classification of lactic acid bacteria into different genera is based on 
morphology, mode of glucose fermentation, growth at different temperatures, configuration 
of the lactic acid produced, ability to grow at high salt concentrations, and acid or alkaline 
tolerance (Pascual, 2004). 
Bacteria belonging to the genus Lactobacillus are considered to be the main LAB and the 
predominant microorganisms in the gastrointestinal and urogenital tracts of humans as well 
as homeotermic animals. They are also used for elaborating different fermented foods 
categorized as GRAS (generally considered as safe).  
Although there are data on simultaneous colonization of the human vagina by two different 
species of Lactobacillus, which can be homofermentative, heterofermentative or a 
combination of both (Kaewsrichan et al., 2006; Pascual et al, 2006), only one species has been 
isolated from the vaginal tract. Also, there are evidences of their effectivity in the prevention 
of urogenital infections (Pascual, 2004; Axelsson, 2004). 
The urogenital microbiota of a healthy woman comprises approximately 50 species of 
organisms, witch differ in composition according to reproductive stages and exposure to 
several factors, including antibiotics and spermicides (Pascual, 2004).   
In the complex vaginal environment, bacteria of the lactobacilli group (107–108 CFU g-1 of 
vaginal fluid) are the dominant microorganisms in healthy pre-menopausal women, and 
play an important protective role by limiting growth of pathogenic microorganisms. When 
lactobacilli are reduced, eliminated, or replaced by pathogenic species, the host has an 
increased susceptibility to urinary tract infections (UTIs), genital tract infections (GTIs), 
bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and infection by Neisseria 
gonorrhoeae or Trichomonas vaginalis. Worldwide studies of UTIs or GTIs have revealed 
increasing antibiotic resistance among pathogenic microorganisms. Our research group has 
isolated human vaginal lactobacilli, selecting those with beneficial or probiotic properties 
(Czaja et al., 2007).  
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Urogenital infections are a major reason for women to visit their family’s physician and are 
generally derived to gastroenterology, gynecology, urology, and infectious diseases 
specialists. The association between abnormal vaginal microbiota and increased risk for 
sexually transmitted infections, bladder and vaginal infections, and a higher rate of preterm 
labor indicate the need to better understand and manage urogenital health (Reid et al., 
2004). Urogenital infections, defined here to include those that affect the bladder, kidneys, 
vagina, urethra, periurethra, and cervix, constitute a worldwide problem (Roos et al., 2006). 
The majority of UTI's occur in sexually active women (Howes et al., 2008). Risk increases by 
3-5 times when diaphragms are used for contraception. Risk also slightly increases with not 
voiding after sexual intercourse and use of spermicides such as nonoxynol-9, which have 
been shown to be toxic to lactobacilli.  Depletion of disturbances of vaginal lactobacilli biota 
has been associated with establishment of opportunistic infections like BV (bacterial 
vaginosis) and an increased risk of acquiring type 1 HIV. Nonoxynol-9 is the active 
compound in many spermicidal formulas. It is a nonionic detergent that reduces the 
superficial tension of the human spermatozoon membrane, causing loss of motility, decrease 
of its glucolytic power and alteration in permeability. It also affects the lipidic content of the 
human spermatozoon membrane. Nonoxynol-9 is generally used at concentrations of 5% in 
creams. It is possible that the presence of N-9 affects the ecological balance of the vagina 
through the inhibition of protective lactobacilli, especially those that produce H2O2.  
Nonoxynol-9 is a spermicide that has antimicrobial activity. Some studies have shown that 
lactobacilli present resistance or sensitivity to this compound (Pascual et al., 2006). 
 Increased risk has not been demonstrated with oral contraceptives, not voiding before 
intercourse, non-cotton underwear, and use of condoms. The prevalence and incidence of 
urinary tract infection is higher in women than in men, which is likely the result of several 
clinical factors including anatomic differences, hormonal effects, and behavior patterns 
(Standiford et al., 2005). 
Historical data indicate that the vast majority of urinary tract infections (UTI) in a suburban, 
nonhospitalized community is caused by Escherichia coli, followed by other Enterobacteriaciae 
and Staphylococcus saprophyticus. The most frequent bacterial cause of UTI in adult women is 
Escherichia coli, which is part of the normal gut microbiota. This organism accounts for 
approximately 85% of community-acquired UTIs and 50% of hospital acquired UTIs (Talan 
et al., 2008). 
However, a recent study reported that by infections E. coli were less common and that 
Enterococcus faecalis was the second most prevalent uropathogen. The latter result was also 
found in hospitalized patients. UTI affect millions of women each year, with an annual 
societal cost of billions of dollars. More than one quarter of women with a UTI will have a 
recurrent infection within six months. There are few established options for prevention of 
UTI other than the use of prophylactic antibiotics. Most uncomplicated UTI cases are 
resolved within 1 to 7 d of antibiotic therapy (Talan et al., 2008). However, drug resistance to 
commonly used antibiotics (eg, trimethoprim/sulfamethoxazole) is increasing among 
uropathogens and patients are experimenting more and more with alternative natural 
medicines, which appear to contain antiadhesive compounds that are active against 
uropathogens and can help prevent UTI (Pascual, 2004). The phenological characteristics of 
the lactobacilli strains including adhesive ability and production of acids, bacteriocins, 
hydrogen peroxide, and biosurfactants appear to be important in conferring protection to 
the host. Therefore, effective nonantibiotic methods of prevention are needed. One potential 
alternative may bee probiotic lactobacilli (Reid et al., 2005; Pascual et al, 2008a). The 
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rationale for the use of probiotics is based on the genitourinary regulatory role played by the 
commensal microbiota and the need for restoration of this microbial ecosystem after insult. 
Health care providers who are interested in the therapeutic potential of probiotics require 
evidence of efficacy from randomized controlled assays, including data on successful local 
colonization and strain-specific outcomes, and information on product integrity and 
stability. This article reviews available information on the efficacy and tolerability of 
probiotics in the treatment and prophylaxis of bacterial vaginosis (BV) and the prophylaxis 
of UTI (Barrons and Tassone, 2008). 
The administration of lactobacilli does not produce adverse effects in the urogenital tract; 
thus, it effectively prevents urinary tract infections. Several clinical assays have 
demonstrated that certain Lactobacillus species can be given orally or vaginally with 
resulting colonization of the vagina, reduction in vaginal coliform counts, and even 
reduction in UTI recurrence (Reid et al.,2004).  
2. Probiotics 
2.1 The history of probiotics  
The first observation of the positive role of some bacteria can be credited to the work of 
Metchinkoff (1908); who reported on the potential health benefits of probiotics after he 
observed that Bulgarian peasants that consumed fermented milk products showed long, 
healthy lives (Sanders, 1999; Senok et al., 2005). At the same time Henry Tissier (1906), a 
French pediatrician, observed that children with diarrhea had in their stools a low number 
of bacteria characterized by a peculiar morphology. These bacteria were, on the contrary, 
abundant in healthy children. He suggested that these bacteria could be administered to 
patients with diarrhea to help restore a healthy gut biota (WHO/ FAO, 2006).  
The application of ‘‘health promoting’’ bacteria for therapeutic purposes has a long tradition 
in medicine; however, this so-called ‘‘bacteriotherapy’’ has long been considered to be a 
nonstandard procedure whose efficacy has not yet been proved or is at most based on 
observation but not on clinical studies (Suvarna and Body; 2005). The successful 
introduction of probiotics to the market has helped and inspired research in this area to a 
huge extent. In recent years, there has been a great increase in the number of clinical studies 
in which the prevention, alleviation, or therapy of diseases has been scientifically 
investigated not only to find evidence for a health claim for a target group of ‘‘healthy 
consumers’’ but also to test the medicinal (preventive and therapeutic) application of 
probiotics (Reid et al., 2006). 
The term “Probiotic” derives from the Greek meaning “for life”. It was first introduced in 
1965 by Lilly and Stillwell for describing substances secreted by one organism which 
stimulate the growth of another (Reid et al., 2003). In 1974, Parker referred to “Probiotic” as 
organisms and substances which contribute to the intestinal microbial balance. However, 
this term was subsequently redefined by Fuller (1989) as a live microbial feed supplement 
which beneficially affects the host animal by improving its intestinal microbial balance 
(Desai, A., 2008). This definition was broadened by Havenaar and Huis in’t Veld (1992) to a 
mono or mixed culture of live microorganisms which benefits man or animals by improving 
the properties of the indigenous microbiota (Klaenhammer, 2000; Ranadheera et al., 2010).  
At present is defined, by FAO/OMS, as “Live microorganisms which, when administered in 
adequate amounts, confer a health benefit on the host” (WHO / FAO, 2001).  In a healthy 
host, a balance exists between members of the microbiota, such that potential pathogenic 
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and non-pathogenic microorganisms can be found in apparent harmony. During infection, 
this balance can become disturbed, leading to often dramatic changes in the composition of 
the microbiota. The most important genus of Gram positive bacteria used extensively as 
probiotics are Lactobacillus and Bifidobacterium  (Table 1).  
 
Lactobacillus spp. Bifidobacterium spp.  Others 
L. acidophilus 
L. rhamnosus 
L. gasseri 
L. casei 
L. reuteri 
L. delbrueckii subsp. 
bulgaricus 
L. crispatus 
L. plantarum 
L. salivarus 
L. johnsonii 
L. gallinarum 
L.plantarum 
L. fermentum 
L. helveticus 
L. paracasei 
L. lactis 
B. bifidum 
B. breve 
B. infantis 
B. longum 
B. lactis 
B. adolescentis 
B.essensis                         
B.laterosporum 
Enterococcus faecalis 
E. faecium 
Streptococcus salivarus subsp. 
thermophilus 
S. termophilus 
Lactococcus lactis subsp. lactis 
L. lactis subsp. cremoris 
Propionibacterium freudenreichii 
Pediococcus acidilactici 
Leuconostoc mesenteroides 
Table 1. Microorganisms applied as probiotics. Ranadheera et al., 2010 and Gupta and Garg, 2009. 
More than 20 years ago, the production of substances that inhibited pathogen growth on 
agar plates or the ability to reduce adherence of pathogens in vitro defined a probiotic (Chan 
et al., 1985). Now, the bar has been raised significantly higher, and use of the term 
‘probiotic’ needs bacteria to be properly speciated, shown in appropriate formulations to be 
safe and effective at conferring health benefits on mammalian hosts, and manufactured and 
sold in a way that accurately reflects what benefits a consumer can obtain (Reid, 2005; 
Corcionivoschi et al., 2010). Sadly, governments and industry have not yet taken these 
requirements to heart, and whereas many so-called probiotic products are available, 
relatively few true probiotic products exist (Table 2). 
2.2 Mechanisms of action 
Mechanisms by which probiotics exert healthy effects are incompletely understood. Some 
authors include competitive inhibition with pathogenic bacteria, effects on barrier function, 
antagonism through the production of antimicrobial substances (acids, hydrogen peroxide 
and bacteriocins) and modulation of the immune system (Cabana et al., 2006; Almeghaiseeb, 
2007). These mechanisms vary according to the specific strain or combination of strains 
used, the presence of prebiotics [a non-digestible food ingredient which beneficially affects 
the host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon having the potential to improve host health (Gupta and Garg, 2009)] 
and the condition that is being treated the patient (Devine and Marsh, 2009). 
Probiotics microorganisms compete with pathogens for nutrients and physical space (Fuller, 
1991; Johannsen,  2003).  
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Table 2. Criteria for selection of probiotic strains. Adapted from Klahenhammer (2007). 
Some bacteria can inhibit and prevent the colonization by pathogenic microorganisms by 
means of a mechanism of steric obstruction or blocking of specific receptors (Amores et al., 
2004).  LGG and L. plantarum have been shown to competitively inhibit the attachment of 
enteropathogenic E. coli 0157H7 to HT-29 human colonic cancer cells (Michail et al., 1997; 
Alvarez-Olmos and Oberhelman. 2001). 
The effect of probiotics may be classified in three modes of action: (i) Probiotics have a direct 
effect on other microorganisms, commensal and/or pathogenic ones. This principle is in 
many cases of importance for the prevention and therapy of infections and restoration of the 
microbial equilibrium. (ii) Probiotics also might be able to modulate the host’s defenses 
including the innate as well as the acquired immune system. This mode of action is most 
likely important for the prevention and therapy of infectious diseases but also for the 
treatment of chronic inflammation. (iii) Probiotic effects may be based on actions affecting 
microbial products like toxins, host products e.g.bile salts and food ingredients 
(Oeslschaeger, 2010). 
3. Probiotics: effects on other microorganisms  
3.1 Production of antimicrobial compounds  
Lactobacilli produce a variety of compounds that are inhibitory to both Gram-positive and 
Gram-negative bacteria. These inhibitory substances include organic acids, bacteriocins, 
hydrogen peroxide and biosurfactants (Rolfe, 2000).  
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3.1.1 Organic acids 
Lactic and acetic acids are the main products of carbohydrates fermentation by LAB. These 
acids diffuse through the membrane of the target organisms, in their hydrophobic 
undissociated form. Inside of the bacterial cytoplasm they are exposed to a pH value near to 
neutrality; subsequently, they dissociate (anion and H+), reduce cytoplasmic pH and reduce 
metabolic activities (Kotikalapudi, 2009; Dalié et al., 2010). This lower cytoplasmic pH 
inhibits glycolysis, prevents active transport and interferes with signal transduction. 
Furthermore, the anionic part of the acid cannot diffuse freely through the cell wall and 
accumulates inside the bacterial cell. Accumulation of anions leads to internal osmotic 
disorders for the bacteria (Kotikalapudi, 2009). 
Among the antimicrobial compounds synthesized by the two human lactobacilli strains 
used in our work, L. fermentum L23 and L. rhamnosus L60, we have only researched the 
antimicrobial activity attributed to the bacteriocins and not necessarily to H202 and lactic 
acid production. In previous reports, our group has shown the probiotic properties and the 
production of metabolites with biological activity against a wide spectrum of other 
microorganisms of these lactobacilli strains (Pascual et al., 2008a; Ruiz et al., 2009). 
Juarez Tomás et al. (2003) tested the antimicrobial activity of lactobacilli strains in vitro 
(Lactobacillus brevis CRL 1335 and L. acidophilus strains CRL 1259, CRL 1307, CRL 1320 and 
CRL 1324). They found that these strains were able to inhibit the growth of E. coli, S. aureus, 
S. agalactiae, E. faecalis, Klebsiella sp., N. gonorrhoeae and G. vaginalis. Inhibition was shown to 
be produced by the low pH of the lactobacilli supernatants, as it disappeared when the 
supernatants were neutralized. 
3.2 Bacteriocins 
Bacteriocins are antimicrobial substances of protein nature, some of which may contain an 
associated lipid or carbohydrate, that inhibit growth of related or unrelated bacterial species 
and are potentially useful for prevention or treatment of bacterial infectious diseases ( Riley 
and Chavan, 2007; Pascual et al., 2008b). 
Bacteriocins produced by lactic acid bacteria are divided into five classes based on primary 
structure, molecular mass, heat stability, and molecular organization : class I, lantibiotics; 
class II, nonlantibiotic peptides (subclass IIa, pediocin-like bacteriocins with strong 
antilisterial activity; subclass Ilb, bacteriocins whose activity depends on complementary 
action of two peptides; subclass Ilc, secdependent secreted bacteriocins); class III, large, heat 
labile protein bacteriocins; class IV, bacteriocins consisting of an undefined mixture of 
protein(s), lipid(s), and carbohydrate(s); and class V, bacteriocins with circular, unmodified 
posttransductional structure (including AS-48, gasericine A, enterocin) (Kemperman et al., 
2003; Gutiérrez Merino J, 2005). 
Lactobacilli bacteriocins are of interest because of their potential application for inhibition of 
pathogenic bacteria that affect humans. Two Lactobacillus strains from human vagina, L. 
fermentum L23 and L. rhamnosus L60, were previously identified and characterized as 
probiotics and producers of bacteriocins.  
In a study carried out by our research group (Pascual et al. 2008a,b), we described the 
isolation, purification, and partial characterization of bacteriocins from L. fermentum L23 
and L. rhamnosus L60. The inhibitory spectrum of these strains was quite broad, including 
Gram-negative and Gram-positive pathogenic strains and Candida species. To evaluate the 
proteinaceous nature of the antibacterial substances, the effect of proteolytic enzymes 
(trypsin, protease VI) was tested. Incubation of samples for 1 h at 37 ºC with these 
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enzymes completely inhibited the antibacterial activity. The bacteriocin produced by L. 
fermentum strain L23 was sensitive to several proteases, indicating that the inhibitory 
material was proteinaceous. Catalase and urease had no effect on its activity. Bacteriocin 
activity was most stable at acid or neutral pH. At alkaline pH, the bacteriocin became 
progressively inactivated. The partially purified bacteriocin was further purified by 
chromatography gel filtration (Sephadex G25). The sample was concentrated by 
evaporation and diluted in a small volume of phosphate buffer at pH 6.5. Fractions of 2.0 
ml were collected, and their activity towards the indicator strain was tested. Fractions F15, 
F16, F17, and F18 displayed inhibitory activity against E. coli. They were pooled and 
concentrated. 
The fraction collected after C18 reversed-phase HPLC exhibited activity against the 
indicator strain E. coli. The corresponding elution profile from reversed-phase HPLC, 
recorded at 220 nm, revealed one peak collected in the fraction eluted at 30 min. When an 
aliquot of the 30-min fraction was subjected to agar well diffusion assay, a zone of inhibition 
was produced in the agar. The fractions with antibacterial activity (F15, F16, F17, F18) 
obtained by chromatography assays were analyzed by TLC on silica gel plates.  
The bacteriocin L23 produced by L. fermentum strain 23 showed a wide inhibitory spectrum, 
including some lactobacilli. A noteworthy observation was the inhibition of the pathogenic 
Gram-negative bacteria E. coli, Proteus vulgaris, P. mirabilis, Klebsiella pneumoniae, and 
Neisseria gonorrhoeae. In general, bacteriocins from lactic acid bacteria are active only 
towards Gram-positive bacteria. A wide inhibitory spectrum, as observed here for L. 
fermentum and L. rhamnosus L60, seems to be common among bacteriocin-producing isolates 
from the genus Lactobacillus (group III). Bacteriocin L23 did not show inhibitory activity 
against species of vaginal microbiota, including lactobacilli. Strain L23 secretes an 
antibacterial substance other than lactic acid, which is heat stable and only moderately 
sensitive to enzyme treatment. Several characteristics of the component responsible for the 
antibacterial activity suggest that it contains an unusual acidic amino acid present in a novel 
peptidic agent (Ruiz et al., 2009). 
3.1.3 Interactions of bacteriocins 
Also, the interactions between pairs of bacteriocins that inhibit the growth of urogenital 
pathogens were studied. To evaluate types of interaction between L23 and L60 bacteriocins, 
207 isolates were considered. Synergistic interaction between these two bacteriocins was 
found in 68.6% of the cases (Fig. 1). Interactions were interpreted based on the shape of the 
inhibition zone, as follows: (1) lack of interaction (indifference) is indicated by growth at a 
right angle; (2) a synergistic effect results in concave growth between the two inhibition 
zones; (3) an antagonistic effect results in a junction in which growth covers the angle 
formed by the inhibition zones. A synergistic effect was observed with inhibition zones > 
2mm compared with each antimicrobial activity of L60 or L23. Bacteriocin interactions were 
also determined using the checkerboard assay as previously described by Petersen et al. 
(2006). The initial concentrations of bacteriocins used in this experiment were at least the 
double of that of MIC. Serial dilutions of bacteriocins of L23 and L60 along the ordinate and 
abscissa were made, respectively, in MRS broth. The fractional inhibitory concentration 
(FIC) indexes (ΣFICs) were calculated as follows: ΣFIC= FIC A + FIC B, where FIC A is the 
MIC of A in the combination/MIC of A alone, and FIC B is the MIC B in the combination / 
MIC of B alone. The FIC was interpreted as follows: synergy, FIC≤0.5; indifference, 
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0.5<FIC<2; antagonism >2. There was neither an indifferent nor an antagonistic interaction 
between the substances evaluated either by qualitative or semi-quantitative method. 
 
 
Fig. 1. Synergistic interaction between bacteriocins from L23 and L60 strains against E. 
cloacae 
 
 
Table 3. Percentage of interactions between bacteriocins produced by Lactobacillus fermentum 
strain L23 and Lactobacillus rhamnosus strain L60. 
Sensitive species that showed synergistic interaction in 100% of cases were: A. baumanii, P. 
aeruginosa, S. epidermidis, S. aureus, S. agalactiae, E. faecalis, P. vulgaris, and N. gonorrhoeae. 
Smaller percentages of synergistic interactions were found for E. cloacae, K. oxytoca, S. 
saprophyticus, K. pneumoniae, C. freundii, and  S. marcescens. Indifferent interaction between 
L23 and L60 bacteriocins was found in 31.4% of the total cases. In addition, the highest 
percentages of indifferent interaction were observed for P. mirabilis and E. coli. Antagonistic 
interaction between L23 and L60 bacteriocins was not observed (Table 3). 
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Mulet-Powell et al. (1998) were the first to describe interactions between bacteriocins from 
lactic acid bacteria 
(LAB). Here, we report rates of inhibitory activity and interactions between two bacteriocins 
produced by two potential probiotics from lactobacilli of human vagina. Mulet-Powell et al. 
showed antagonistic interaction between LAB bacteriocins, whereas we found no 
antagonistic interaction between L23 and L60 from cell-free supernatants (Ruiz et al., 2009). 
3.1.4 Hydrogen peroxide 
Hydrogen peroxide (H2O2) is produced by most LAB in the presence of oxygen. LAB are 
unable to produce catalase; therefore, they can not degrade hydrogen peroxide that, after 
accumulation, develops its oxidative properties with the production of powerful oxidants 
such as singlet oxygen, superoxide radicals, and the hydroxyl radical. Reactive oxygen 
species can cause irreversible damage to a number of cell components such as enzymes, 
membrane constituents and DNA (Schurman, 2001; Dalié et al., 2010). 
H2O2 is produced by many Lactobacillus strains in different amounts. There are techniques 
for measuring these compounds. In a qualitative method that was carried out by 
Eschenbach et al. (1989), a LAB strain was plated onto MRS agar containing 5 mg 3,3’,5,5’-
tetramethylbenzidine (TMB) and 0,2 mg horseradish peroxidase (HRPO). Peroxidase 
generates O2 from H2O2 and TMB dyes the colonies with a blue color when oxidation occurs 
in the presence of O2 (Pascual et al., 2008a). Pick and Mizel’s phenol red solution method 
was used for testing H2O2 production by macrophages. This quatitative method is modified 
when working with BAL strains. A 50 µl aliquot of centrifuged microorganisms is placed 
onto a 96-well plate. Then,  50 ml of reagent 1 (2 ml of phenol red, 2 ml of HRPO, 46 ml 
DPBS buffer and 10 ml 1N sodium hydroxide) is added. H2O2 was measured indirectly by 
the 600nm absorbance of phenol red (Strus et al., 2005). As was described in previous studies 
by our group, a number of cultured lactobacilli generate hydrogen peroxide at inhibitory 
levels on many pathogenic genitourinary microorganisms. Production of H2O2 by the 
Lactobacillus species is considered to represent a nonspecific antimicrobial defense 
mechanism of the normal vaginal ecosystem. Eschenbach et al. (1989) detected 96% H2O2-
producing (LB+) strains. In the present study, we found 62% LB+ and 38% non- H2O2-
producing strains (LB-). Species with the largest number of LB+ strains were L. acidophilus 
and L. fermentum.  
3.1.5 Biosurfactants 
Biosurfactants are microbial amphiphilic polymers and polyphilic polymers that tend to 
interact with the boundary between two phases in a heterogeneous system, defined as the 
interface (Rivardo et al., 2009; Gudin et al., 2010). They comprise a wide range of chemical 
structures, such as glycolipids, lipopeptides, polysaccharide–protein complexes, 
phospholipids, fatty acids and neutral lipids. Several biosurfactants exhibit antibacterial, 
antifungal and antiviral activities (Gudin et al., 2010). These molecules alter surface 
hydrophobicity and therefore inhibit the adhesion of pathogenic microorganisms to 
infection sites. The release of biosurfactants by probiotic bacteria in vivo can be considered as 
a defence mechanism against other colonizing strains in the urogenital tract (Rodrigues et 
al., 2006; Gudin et al., 2010). Reid and Bruce (2001c) found that L. fermentum RC-14 produces 
large amounts of biosurfactants. These compounds inhibit the adhesion of a broad spectrum 
of urogenital pathogens. 
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3.2 Immune modulation  
Recent studies have clarified the importance of the immunoregulatory ability of probiotics 
for exertion of their preventive and therapeutic effects on several diseases. The epithelial 
barrier consists of a dense mucous layer containing secretory IgA and antimicrobial 
peptides as well as dynamic functional complexes that regulate permeability between cells 
(Ohland and MacNaughton, 2010). When barrier function is interrupted due to several 
factors such as chronic psychological stress, epithelial ion secretion and permeability is 
enhanced, binding of luminal bacteria to surface epithelia increases, the uptake of luminal 
antigens through follicle associated epithelium increases and mucosal inflammation  
initiates (Zareie et al., 2006). There is evidence that consumption of probiotic strains can 
improves the integrity of the intestinal barrier and the upregulation of mucin production 
(Devine and Marsh, 2009).  
Stimulation and modulation of the mucosal immune system by probiotics  reduces 
production of pro-inflammatory cytokines through activity on NFkB pathways, increase in 
production of anti-inflammatory cytokines, such as IL-10 and host defence peptides such as 
b-defensin 2, enhancement in IgA defences and influence on dendritic cell maturation 
(Devine and Marsh, 2009). It has also been shown that probiotics are able to regulate 
linfocite cell proliferation in vitro, as well as the production of specific and nonspecific 
antibodies (Amores et al., 2004). 
The immune system is roughly divided into the acquired immune system, consisting mainly 
of B lymphocytes and sensitized T lymphocytes, and the innate immune system, consisting 
mainly of macrophages and NK cells. The ratio of involvement of the systems varies 
depending on conditions of infection such as species of microorganisms and the amount and 
site of infection. Mouse studies have clarified that direct activation of macrophages by 
probiotics increased the bactericidal effect of macrophages on pathogenic bacteria. 
Probiotics strains have also been reported to promote proliferation of phagocytes such as 
macrophages and neutrophils in the bone marrow and spleen (hematopoietic tissues). Thus, 
activation of the innate immune system may be important in the infection preventing effect 
of probiotics. However, probiotics are also able to protect the integrity of the mucosal barrier 
against the destructive action of pathogenic microorganisms (Oelschlaeger T, 2010).  
3.3 Probiotic effects on microbial toxins 
One of the most important groups of bacterial virulence factors are toxins. The effectiveness 
of certain probiotics in suppressing diarrhoea is most likely based on their ability to protect 
the host against toxins. This protection can result from inhibition of toxin expression in 
pathogens. Certain probiotics are even able to protect against cyanobacterial and fungal 
toxins. The basis of the observed protective effect is rather a physicochemical interaction 
between toxin and a probiotic than a metabolic inactivation (Musa et al., 2009; Oelschlaeger, 
2010). This mechanism of action of probiotics is not considered in this chapter. 
4. Benefical properties of probiotics 
Lactobacilli are able to interfere with genitourinary pathogens by several mechanisms. 
Other functions of lactobacilli include competitive exclusion of pathogens from the cell 
surface, co-aggregation with certain pathogenic bacteria, adherence to epithelial cells and 
biofilm formation based on autoaggregation and surface hydrophobicity (Dunne et al., 
2001). Previous studies indicated that autoaggregation of probiotic strains is necessary for 
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adherence to vaginal epithelial cells, and that co-aggregation leads to formation of a barrier 
that prevents colonization by pathogens (Boris et al., 1998; Zhou et al., 2004). These are some 
of the desired characteristics by which specific vaginal lactobacilli strains were selected as 
potential probiotic agents.  
4.1 Autoaggregation assay  
The aggregation ability could be described as the clumping of cells of the same strain, 
known as autoaggregation or self-aggregation (Nikolic et al., 2010). 
In a study performed by our research group, autoaggregation was described as the ability to 
form aggregates within 2 min. (Andreu et al., 1995). Necessary characteristics for 
Lactobacillus strains to serve as effective prophylactic agents include avid adherence to 
vaginal epithelial cells, interference with the adherence of other bacteria, production of 
bacteriocins, and production of hydrogen peroxide capable of inhibiting the growth of 
pathogens (Zhou et al., 2004). 
4.2 Surface hydrophobicity  
The surface hydrophobicity of lactobacilli was studied by the salt-aggregation test (SAT). 
The lowest final concentration of ammonium sulfate causing the bacteria to aggregate was 
defined as the SAT value. Strains were classified into three groups: high surface 
hydrophobicity (SAT< 0.9 mol/L), intermediate hydrophobicity (SAT 0.9-1.5 mol/L), and 
hydrophilic (SAT> 1.5 mol/L) (Andreu et al., 1995). Two lactobacilli strains studied by our 
group showed high hydrophobicity. Thus, we conclude that hydrophobicity is an important 
mechanism in bacterial adherence. 
4.3 Co-aggregation assays 
Co-aggregation of probiotic bacterial strains has been suggested to enable them to form a 
physical-chemical barrier that prevents colonization by pathogenic bacteria. Lactobacilli 
have been found to co-aggregate with some uropathogenic bacteria and inhibit their growth. 
A co-aggregation assay is positive when lactobacilli produce aggregates with other strain 
(Reid et al., 1990). Lactobacillus fermentum L23 and L. rhamnosus L60 showed co-aggregation 
with E. coli, G. vaginalis, and Candida albicans, but not with C. glabrata (Pascual et al., 2008a). 
Such co-aggregation could be an important factor in maintaining vaginal health because it 
produces an area around the pathogen where the concentration of antimicrobial substances 
produced by these lactobacilli is increased. This would constitute an important host defense 
mechanism against infection (Kotikalapudi, 2009; Taheri et al., 2009). 
4.4 Bacterial adherence  
The ability to adhere to epithelial surfaces is considered an indispensable pre-requisite of 
probiotic strains in order to colonise and then to exert health promoting effects. Bacterial 
adhesion is initially based on non-specific physical interactions between two surfaces (like 
hydrophobic interaction), which then enable specific interactions between adhesins (usually 
proteins) and complementary receptors (Kos et al., 2003; Canzi et al., 2005). To identify 
bacterial traits related to adhesion ability, potential probiotics strains could be assayed for 
adherence to cell lines or more frequently, to individual epithelial cells isolated from tissue 
surfaces by mechanical scraping, brushing or by freezing followed by a rapid thawing 
(Sillanpää, 2001). Some microorganisms are able to bind to epithelial cells of the 
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gastrointestinal tract through lectins present in their surface structures. Lectins are 
carbohydrate-binding proteins or glycoproteins from non-immune origin which agglutinate 
cells with receptors (Gusilis, et al. 2002). Several authors observed a good correlation 
between adhesion ability and cell surface hydrophobicity (Canzi et al., 2005). Adherence was 
assessed by counting the number of bacteria adhered to the intact epithelial cells. The 
number of adhering lactobacilli in the present study was comparable. Such adherence may 
promote colonization of the vaginal epithelium through formation of a bacterial "film" that 
tends to exclude pathogens from the mucosa  ( Reid and Burton , 2002; Pascual et al., 2008a). 
4.5 Competitive exclusion  
Several studies reported that adhesive probiotic bacteria can prevent the attachment of 
pathogens and remove them from the urogenital tract. Studies showed that indigenous 
bacteria isolated from cervical, vaginal, and urethral surfaces of healthy women are able to 
adhere to human uroepithelial cells in vitro. These microorganisms were found to block the 
adherence of uropathogenic bacteria to uroepithelial cells from women with and without a 
history of urinary tract infections. Competitive exclusion was most effective with whole 
viable cells and less effective with cell wall fragments. Analysis of the Lactobacillus cell wall 
preparations suggested that lipoteichoic acid was responsible for the adherence of the 
Lactobacillus cells to uroepithelial cells but that steric hindrance was the major factor in 
preventing the adherence of uropathogens. Microbiota from the urinary tract may be used 
as protection against the attachment of uropathogens to the surfaces of uroepithelial cells 
(Revolledo et al., 2006; Kotikalapudi, 2009).  
5. Applications and beneficial effect of probiotics 
There is preliminary evidence that probiotic microorganisms may antagonize the growth 
of nosocomial pathogens on inanimate surfaces. Among the several health benefits 
attributed to probiotic bacteria, the modulation of the intestinal microbiota of the host and 
the capacity to interact with the immune system directly or mediated by the 
autochthonous microbiota are basic mechanisms. Well-recognized probiotic effects are: 1. 
Prevention of rotavirus-induced or antibiotic-associated diarrhea as well as alleviation of 
lactose intolerance symptoms. 2. Reduction of the concentration of cancer-promoting 
enzymes. 3. Prevention and alleviation of gastrointestinal tract problems in healthy 
people. 4. Beneficial effects on inflammatory diseases of the gastrointestinal tract 
(Helicobacter pylori infection). 5. Normalization of stool passage in subjects with 
obstipation or an irritable colon. 6. Prevention of allergies and atopic diseases in infants.  
7. Prevention of respiratory tract infections. 8. Prevention as well as treatment of 
urogenital infections and 9. Hypocholesterolemic  effect. Evidence suggests that probiotic 
microorganisms may have a role in lowering the incidence of vaginal candidiasis, 
bacterial vaginosis and recurrent lower urinary tract infections (de Vrese and 
Schrezenmeir, 2008). Certain microorganisms, like S. aureus and E. coli, are able to adhere 
to inanimate surfaces by forming biofilms, which consist of an extracellular matrix of 
polysaccharides. Biofilm formation provides these microorganisms with a survival 
advantage against their planktonic competitors, and is an optimal environment for 
proliferation, gene transfer, and quorum sensing within the bacterial population. In this 
sense, it has been shown that probiotic microorganisms, such as Lactobacillus spp., can 
produce multifunctional molecules, known as biosurfactants, which have antagonistic 
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antiadhesive properties against microbial pathogens. Biosurfactants, which are 
amphipathic molecules, have so far found limited application in biomedical sciences; 
however, indications of their potential clinical applicability are increasing (Falagas and 
Makris , 2009).  
The probiotic concept has focused on two principal areas: Health and human nutrition, and 
health and animal production. In this chapter we will approach to the study of probiotics in 
human health. 
5.1 Probiotics in human health 
Several studies have shown the positive use of probiotics in diverse human health problems. 
They are considered to offer potential therapeutic applications in the prevention and 
treatment of different diseases (Anuradha et al., 2006; Harish and Varghese, 2006; Rao et al., 
2009). 
5.2 Urogenital tract infections 
Among women producing estrogen or receiving estrogen supplementation, the largest part 
of the vaginal flora consists of lactobacilli, which possesses antimicrobial properties that 
regulate urogenital microbiota. Genitourinary infections in women are often characterized 
by an alteration in the local flora from a predominance of lactobacilli to coliform 
uropathogens as a result of hormone deficiency, sexual activity, contraceptive measures, 
and other factors (Forsum et al., 2005). 
In the complex vaginal environment, bacteria of the lactobacilli group (107–108 CFU g-1 of 
vaginal fluid) are the predominant microorganisms in healthy pre-menopausal women and 
play an important protective role by limiting growth of pathogenic microorganisms (Reid, 
2005; Anukam et al., 2006; Pascual et al., 2008a). When lactobacilli are reduced, eliminated or 
replaced by pathogenic species, the host has an increased susceptibility to urinary tract 
infections (UTIs), genital tract infections (GTIs), bacterial vaginosis (BV), vulvovaginal 
candidiasis (VVC), and infection by N. gonorrhoeae or Trichomonas vaginalis (Reid et al, 2003; 
Klebanoff et al., 2004, Ruíz et al., 2009) 
The use of probiotics per se and mainly lactobacilli has received greater attention as an 
alternative, inexpensive and natural remedy to restore and maintain the genitourinary 
health (Reid, 2001a,c).  
Reid et al. (2001b)  reported the first clinical evidence that probiotic lactobacilli can be 
delivered to the vagina following oral intake, strain L. rhamnosus GR-1 and  L. fermentum RC-
14 were suspended in skim milk and given twice daily for 14 days to 10 women with a 
history of recurrent yeast vaginitis, bacterial vaginosis  and urinary tract infections. Six cases 
of asymptomatic BV or intermediate BV were resolved within 1 week of treatment.  Also,  a  
recent clinical  trial  showed  that  oral  administration  of  capsules containing  L.  fermentum 
RC-14  and  L.  rhamnosus GR-1 was effective  as  adjuvant  in  the  treatment  of  patients  
diagnosed with VVC (Gil et al., 2010).   
Pascual et al. (2010) found that L. fermentum L23 isolated from vaginal swabs of healthy, non-
pregnant, pre-menopausal woman was able to prevent and cure Escherichia coli infection in a 
murine vaginal tract model. The study of vaginal colonization by lactobacilli showed that 
the human L. fermentum L23 strain had the ability to colonize the vaginal tract. A single 
inoculation was sufficient to establish the probiotic lactobacilli into that niche. Vaginal tract 
levels of L. fermentum L23 remained fairly high for 4 days, with bacterial levels ranging from 
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4.6 to 3.8 log10 c.f.u. ml-1. On day 5, values decreased to 2.6 log10 c.f.u.ml-1. No growth of L23 
strain was observed thereafter (Fig. 2). Infection with the pathogen was maintained in the 
vaginal tract for more than 7 days (Fig. 3), and this human E. coli uropathogenic strain was 
able to produce a strong infection when inoculated at this concentration, producing 
significant morphological alterations of the mucosal structure, mainly due to infiltration of 
polymorphonuclear cells. 
The test on the preventive effect produced by strain L23 showed that a single administration of  
Lactobacillus (1x108 u.f.c. ml-1) inhibited E. coli growth and, on the third post-infection day,  the 
E. coli growth was not detected, showing that the pathogen was eliminated by the probiotic 
strain (Fig. 4). The curative effect produced by L23 showed complete inhibition of pathogen’s 
growth after 5 days of treatment (Fig. 5). Thus, L. Fermentum, at that concentration, effectively 
eliminated E. coli from the vagina and had no negative effect on the host. 
 
 
Fig. 2. BALB/c mice vaginal colonization by L. fermentum L23. Results are shown as 
means±SD. 
 
 
Fig. 3. Vaginal infection of E. coli in female mice. Results are shown as means±SD. 
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Fig. 4. Preventative effect of L. fermentum L23 (о) on E. coli () in BALB/c mice. Results are 
shown as means±SD. Significant differences between the untreated control (Fig. 3) and the 
treated group were found (P<0.05). 
 
 
Fig. 5. Curative effect of L. fermentum L23(о)  on E. coli() in female BALB/c mice. Results 
are shown as means±SD. 
6. Safety considerations 
Probiotics are viable microorganisms, and therefore it is feasible that they could infect the 
host. First selection criteria mentioned that a probiotic supplement have to be generally 
regarded as safe microorganisms (Reid et al., 2003; Cabana et al., 2006). Species of 
Lactobacillus or Bifidobacterium are normal residents of the gastrointestinal and/or vaginal 
microbiota and do not display infectivity or toxicity. The risk of infection with these 
microorganisms is lower (World Gastroenterology Organization Practice Guideline, 2008; 
Gupta and Garg, 2009). 
Probiotics are safe for using in healthy people, but should be used with caution in high risk 
cases such as: People with immune compromise and premature infants. Current WHO/FAO 
guidelines (2001) recommend that, before using probiotic strains, a number of parameters 
should be evaluated to prevent health damages, including antibiotic susceptibility patterns, 
toxin production, metabolic and haemolytic activities, infectivity in immunocompromised 
animal models, side-effects and adverse incidents in humans (Senok et al., 2005). 
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7. Conclusion 
This chapter focuses on a group of lactobacilli, which may protect the vaginal epithelium 
through a series of barrier mechanisms (adherence), interference mechanisms (co-
aggregation with potential pathogens), and production of antimicrobial substances. They 
appear to be excellent candidates for development as prophylactic agents. The L. fermentum 
L23 and L. rhamnosus L60 strains were selected for further studies of possible therapeutic 
application in the vaginal tract. Further studies are needed to evaluate their 
immunomodulatory capabilities.The bacteriocins produced by these lactobacilli are strong 
candidates for treatment or prevention of urogenital disorders in women. 
Probiotics do not represent a magic result, but evidence is accumulating that the use of 
probiotic strains and manipulation of the host's own vaginal/urethral microbiota will 
provide valuable options to help restore and maintain urogenital health. Once appropriate 
product formulations with supporting clinical data become available, it will be up to the 
physician to determine their place in patient management. 
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